InDex Pharmaceuticals discontinues cobitolimod phase III program
/PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) ("InDex Pharmaceuticals") today announces that an independent DMC has completed the planned dose...
Source: prnewswire.com
Page 2 - Induction Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Induction Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Induction Study Today - Breaking & Trending Today
InDex Pharmaceuticals announces that all patients needed for the cobitolimod dose selection milestone have completed Ind
STOCKHOLM, Oct. 11, 2023 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that 30% of...
Source: europapress.es
InDex Pharmaceuticals is attending the UEGW 2023 congress
/PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) will attend the United European Gastroenterology Week (UEGW), one of the world's leading...
Source: prnewswire.com
InDex Pharmaceuticals announces license agreement with Viatris Japan to develop and commercialize cobitolimod in Japan
STOCKHOLM, May 31, 2023 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) ("InDex") today announced that a license agreement has been signed with Viatris Pharmaceutical Japan Inc. ("Viatris
Source: finanznachrichten.de
InDex Pharmaceuticals announces license agreement with Viatris Japan to develop and commercialize cobitolimod in Japan
May 31, 2023 - InDex Pharmaceuticals Holding AB today announced that a license agreement has been signed with Viatris Pharmaceutical Japan Inc. to register and commercialize cobitolimod in Japan... | June 7, 2023
Source: marketscreener.com